BiotechTube

Amifampridine Phosphate + Placebo Oral Tablet

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lambert-Eaton Myasthenic Syndrome

Conditions

Lambert-Eaton Myasthenic Syndrome

Trial Timeline

Nov 1, 2016 → Oct 1, 2017

NCT ID
NCT02970162

About Amifampridine Phosphate + Placebo Oral Tablet

Amifampridine Phosphate + Placebo Oral Tablet is a phase 3 stage product being developed by Catalyst Pharmaceuticals for Lambert-Eaton Myasthenic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02970162. Target conditions include Lambert-Eaton Myasthenic Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT03781479Phase 2Completed
NCT03304054Phase 3Completed
NCT02970162Phase 3Completed

Other Products from Catalyst Pharmaceuticals

Amifampridine Phosphate + PlaceboPhase 3
72
amifampridine phosphate + PlaceboPhase 3
72
Amifampridine Phosphate + Placebo Oral TabletPhase 3
72
Amifampridine PhosphatePhase 3
72
Vigabatrin + Matching PlaceboPhase 2/3
60